Predictive factors in eradicating hepatitis C virus using a relatively small dose of interferon

Journal of Gastroenterology and Hepatology (Australia)

Volumn 13, Issue 4, 1998, Pages 412-418

  Fukuda, Mizuho ^a   Chayama, Kazuaki ^a   Tsubota, Akihito ^a   Kobayashi, Masahiro ^a   Hashimoto, Michie ^a   Miyano, Yukiko ^a   Koike, Hiromi ^a   Kobayashi, Mariko ^a   Koida, Isao ^a   Arase, Yasuji ^a   Saitoh, Satoshi ^a   Murashima, Naoya ^a   Ikeda, Kenji ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

HCV; Interferon; Interferon dose; Interferon sensitivity determining region

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; BETA INTERFERON;

AMINO ACID SUBSTITUTION; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CODON; DOSE RESPONSE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; PRIORITY JOURNAL; VIRUS GENE; VIRUS LOAD;

EID: 7144260399     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1998.tb00656.x     Document Type: Article

References (31)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-62.
2. Kuo G, Choo QL, Alter HJ et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244: 362-4.
3. Dienstag JL. Non-A, non-B hepatitis. I. Recognition, epidemiology, and clinical features. Gastroenterology 1983; 85: 439-62.
4. Koretz RL, Stone O, Mousa M, Gitnick GL. Non-A, non-B post-transfusion hepatitis- a decade later. Gastroenterology 1985; 88: 1251-4.
5. Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alpha; a multicenter randomized, controlled trial. N. Engl. J. Aed. 1989; 321: 1501-6.
6. Di Bisceglie AM, Martin P, Kassianides C et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized double blinded, placebo-controlled trial. N. Engl. J. Med. 1989; 321: 1506-10.
7. Chayama K, Kobayashi M, Saitoh S et al. Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C. Hepatology 1001; 3: 1040-3.
8. Shindo M, Di Bisceglie AM, Cheung L et al. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann. Intern. Med. 1991; 115: 700-4.
9. Garson JA, Tedder RS, Briggs M et al. Detection of hepatitis C viral sequences in blood donations by 'nested' polymerase chain reaction and prediction of infectivity. Lancet 1990; 335: 1419-22.
10. Chayama K, Kobayashi M, Saitoh S et al. Sensitive and specific detection of hepatitis C virus RNA with nested polymerase chain reaction and digoxigenin labeled cDNA probe. Acta Hepatol. Jpn 1991; 32: 136-40.
11. Hayashi J, Ohmiya M, Kishihara Y et al. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am. J. Gastroenterol. 1994; 89: 2151-6.
12. Kumada T, Nakano S, Takeda I et al. Long-term administration of natural interferon-alpha in patients with chronic hepatitis C: Relation to serum RNA concentration, HCV-RNA genotypes, histological changes and hepatitis C virus. J. Gastroenterol. Hepatol. 1996; 11: 159-65.
13. Matsumoto A, Tanaka E, Suzuki T, Ogata H, Kiyosawa K. Viral and host factors that contribute to efficacy of interferon-alpha 2a therapy in patients with chronic hepatitis C. Dig. Dis. Sci. 1994; 39: 1273-80.
14. Chayama K, Arase Y, Koida I et al. Antiviral effect of lymphoblastoid interferon-alpha on hepatitis C virus in patients with chronic hepatitis type C. J. Gastroenterol. Hepatol. 1994; 9: 128-33.
15. Chemello L, Bonetti P, Cavalletto L et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995; 22: 700-6.
16. Van-Thiel DH, Friedlander L, Fagiuoli S, Molloy P, Kania RJ, Wright H. The Oklahoma-Pittsburgh experience with interferon alpha in the treatment of HCV disease. J. Okla. State Med. Assoc. 1995; 86: 154-61.
17. Enomoto N, Sakuma I, Asahina Y et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N. Engl. J. Med. 1996; 334: 77-81.
18. Urdea MS, Horn T, Fultz TJ et al. Branched chain DNA amplification multimers for the sensitive, direct detection of human hepatitis viruses. Nucleic Acids Res. 1991; 24: 197-200.
19. Chayama K, Tsubota A, Arase Y et al. Quantitative analysis of hepatitis C virus RNA by competitive nested polymerase chain reaction. J. Gastroenterol. Hepatol. 1993; 8: S40-4.
20. Tanaka E, Kiyosawa K, Matsumoto A, Kashiwakuma T, Hasegawa A, Mori H. Serum levels of hepatitis C virus core protein in patients with chronic hepatitis C treated with interferon alpha. Hepatology 1996; 23: 1330-3.
21. Chayama K, Tsubota A, Arase Y et al. Genotypic subtyping of hepatitis C virus. J. Gastroenterol. Hepatol. 1993; 8: 150-6.
22. Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A non-B hepatitis. Proc. Natl Acad. Sci. USA 1990; 87: 9524-8.
23. SAS Institute Inc. SAS/STAT User's Guide, Release 6.03 edn. Cary: SAS Institute Inc., 1988.
24. Hino K, Sainokami S, Shimoda K et al. Genotypes and titers of hepatitis C. virus for predicting response to interferon in patients with chronic hepatitis C. J. Med. Virol. 1994; 42: 299-305.
25. Garson JA, Brillanti S, Whitby K et al. Analysis of clinical and virological factors associated with response to alpha interferon therapy in chronic hepatitis C. J. Med Virol. 1995; 45: 348-53.
26. Laurent P, Dussaix E, Altman C et al. Host and viral characteristics affecting the response to interferon therapy in chronic hepatitis C. Eur. J. Gastroenterol. Hepatol. 1995; 7: 335-40.
27. Hwang SJ, Chan CV, Lu RH, Wu JC, Lee SD. Randomized controlled trial of recombinant interferon-alpha 2b in the treatment of Chinese patients with chronic hepatitis C. J. Interferon Cytokine Res. 1005; 15: 611-16.
28. Yoo SK, Kim SS, Park YM et al. Predictive factors for beneficial response to interferon-alfa therapy in chronic hepatitis C. Korean J. Intern. Med. 1905; 10: 94-102.
29. Jenkins PJ, Cromie SL, Bowden DS, Finch CF, Dudley FJ. Chronic hepatitis C and interferon alfa therapy: predictors of long term response. Med. J. Aust. 1996; 164: 150-2.
30. Pawlotsky J, Roudot-Thoraval F, Bastie A et al. Factors affecting treatment responses to interferon-α in chronic hepatitis C. J. Infect. Dis. 1006; 174: 1-7.
31. Chemello L, Cavalletto L, Casarin C et al. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-α in chronic hepatitis C. Ann. Intern. Med. 1006; 124: 1058-60.